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Mechanisms of p53 Restriction in Merkel Cell
Carcinoma Cells Are Independent of the Merkel Cell
Polyoma Virus T Antigens
Roland Houben1, Christina Dreher1, Sabrina Angermeyer1, Andreas Borst1, Jochen Utikal2,3,
Sebastian Haferkamp1, Wiebke K. Peitsch3, David Schrama1,4 and Sonja Hesbacher1
Merkel cell carcinoma (MCC) is a rare and very aggressive skin cancer with viral etiology. The tumor-associated
Merkel cell polyoma virus (MCV) belongs to a group of viruses encoding T antigens (TAs) that can induce
tumorigenesis by interfering with cellular tumor-suppressor proteins like p53. To explore possible modes of p53
inactivation in MCC p53 sequencing, expression analysis and reporter gene assays for functional analyses were
performed in a set of MCC lines. In one MCV-negative and one MCV-positive cell line, p53 inactivating mutations
were found. In the majority of MCC lines, however, wild-type p53 is expressed and displays some transcriptional
activity, which is yet not sufficient to effectively restrict cellular survival or growth in these cell cultures.
Interestingly, the MCV TAs are not responsible for this critical lack in p53 activity, as TA knockdown in MCV-
positive MCC cells does not induce p53 activity. In contrast, inhibition of the ubiquitin ligase HDM-2 (human
double minute 2) by Nutlin-3a leads to p53 activation and p53-dependent apoptosis or cell cycle arrest in five out
of seven p53 wild-type MCC lines, highlighting p53 as a potential target for future therapies of this aggressive
tumor.
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INTRODUCTION
Merkel cell carcinoma (MCC) of the skin is a rare and very
aggressive neuroendocrine tumor with more than 3-fold rise in
incidence over the past decades (Hodgson, 2005). As MCC
has a high tendency to metastasize, and there are no curative
or life-prolonging therapies available for patients with
distant metastases (Tai et al., 2000; Becker, 2010), there is a
great need to understand the molecular events driving this
cancer.
Until recently, virtually nothing was known about
oncogenes and tumor suppressors contributing to the patho-
genesis of MCC (Lemos and Nghiem, 2007). However, an
important step forward was the discovery of the Merkel cell
polyoma virus (MCV) that is clonally integrated in the genome
of the cancer cells in the majority of MCCs (Feng et al., 2008;
Sastre-Garau et al., 2009). Integration of the virus before
clonal expansion of the tumor cells as well as addiction
of MCV-positive MCC cells to the expression of viral
oncoproteins suggest that MCV is a major driver of MCC
development and progression (Houben et al., 2010, 2012a).
The polyomaviruses oncoproteins are the T antigens (TAs).
All polyomaviruses encode alternatively spliced Large
and small T antigen (LT and sT). Further splice variants are
middle T antigen, 17 kT and 57 kT, that are encoded by
murine polyomaviruses, simian virus 40 (SV40) and MCV,
respectively (Shuda et al., 2008; Cheng et al., 2009; Gjoerup
and Chang, 2010). Oncogenic transformation by the viral TAs
is mediated by interaction with a multitude of cellular
proteins. For example, protein phosphatase 2A is targeted by
SV40 sT, whereas SV40 LT is capable of inactivating the
tumor-suppressor proteins retinoblastoma protein and p53
(Gjoerup and Chang, 2010).
p53—also referred to as guardian of the genome—is a
transcription factor that can modulate the expression of
hundreds of genes (Song and Xu, 2007). In normal cells,
p53 is frequently undetectable because of continuous
ubiquitination by HDM-2 (human double minute 2) and
subsequent proteasomal degradation (Blagosklonny, 1997).
On several types of stresses including DNA damage or
oncogene activation, p53 gets activated and induces
cell cycle arrest, DNA repair, apoptosis, or senescence
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(Green and Chipuk, 2006; Lavin and Gueven, 2006; Sherr,
2006). Thereby, p53 is central for the suppression of cancer,
and its inactivation is one of the characteristics of cancer.
Indeed, mutations of p53 are found in approximately half of
all tumors (Roemer, 1999). Most of these aberrations are
missense mutations in the central DNA-binding domain that
abolish the transcriptional capacity and may render p53
dominant negative over coexpressed wild-type p53 (van
Oijen and Slootweg, 2000). Beside mutations, further modes
of p53 inactivation contributing to tumor development have
been described, including the ability of certain viral proteins
to impair p53 function. Indeed, p53 inactivation is a common
feature of all DNA tumor viruses (Levine, 2009).
p53 inactivation by polyomaviruses was described mainly
as a function of LT that binds to p53 and thereby abrogates its
ability to act as a transcription factor (Bargonetti et al., 1992;
Jiang et al., 1993; Pipas and Levine, 2001). MCV LTs in MCC
cells, however, lack a putative p53-binding domain because
of tumor-associated T-antigen deletion mutations generally
present in MCC-associated MCV genomes (Shuda et al., 2008;
Sastre-Garau et al., 2009). Nevertheless, recent reports
suggested that mutations in p53 occur preferentially in MCC
tumors that fail to express MCV LT (Sihto et al., 2011; Rodig
et al., 2012). For example, p53 mutations were found in over
50% of MCCs lacking MCV LT expression but were not
detectable in LT-positive MCCs (Sihto et al., 2011). These
observations suggest that even MCV with truncated LT is able
to inactivate p53. In line with this notion, it has been reported
that, on one hand, SV40 LT lacking the C-terminal
p53-binding domain is still able to inhibit p53-dependent
transcription (Quartin et al., 1994; Rushton et al., 1997)
and, on the other hand, SV40 sT can repress p53 function
(Gjoerup et al., 2000).
Here we analyze the p53 signaling pathway in MCV-
positive and MCV-negative MCC lines. Most of these cell
lines harbor wild-type but insufficiently active p53 protein.
We exclude the MCV TAs as relevant inhibitors of p53 activity
in MCC and demonstrate that p53-dependent cell death or cell
cycle arrest can be activated by a small-molecule inhibitor of
HDM-2.
RESULTS AND DISCUSSION
p53 inactivating mutations in 2 of 14 MCC lines
The frequency of p53 inactivating mutations has been reported
to be relatively low in MCC, i.e., 10% (1 in 10 tumors),14%
(3 in 21 tumors) or 27% (11 in 40 tumors) (Van Gele et al.,
2000; Lassacher et al., 2008; Sihto et al., 2011). Thus, as a first
step of a comprehensive p53 pathway analysis in MCC, we
determined the p53 status in 14 MCC lines by sequencing
exons 5–8 in a series of 14 MCC lines. We found that similar
to the published tissue analyses only two MCC cell lines (14%)
had p53 mutations, whereas the remaining 12 cell lines
displayed wild-type sequences in the p53 mutation hot spot
region (Table 1).
Table 1. MCV and p53 status of the MCC cell lines analyzed in this study
Response to Nutlin-3a
MCV þ
p53 status
(exons 5–81)
p53
mRNA
p53
protein
p53-specific
reporter
activity
p53
protein
Reporter
activity
p53
targets
Cycle
arrest Apoptosis
1 BroLi Yes Wild type þ þ þ þ þ þ  þ
2 WaGa Yes Wild type þ þ þ þ þ þ þ  þ
3 Mkl-1 Yes Wild type þ þ þ þ þ þ þ  þ
4 MKL-2 Yes Wild type þ þ       
5 PeTa Yes Wild type þ þ þ þ þ þ þ  þ
6 MS-1 Yes Hemizygous
deletion
aa 251–253
þ þ þ þ þ ? ND ND ND ND ND
7 AlDo Yes Wild type þ þ þ ND ND ND ND ND ND
8 WoWe Yes Wild type ND ND ND ND ND ND ND ND
9 HeRo Yes Wild type ND ND ND ND ND ND ND ND
10 KaRi Yes Wild type ND ND ND ND ND ND ND ND
11 LoKe Yes Wild type ND ND ND ND ND ND ND ND
12 MCC
26
No Wild type þ       
13 UISO No Wild type þ þ þ þ þ þ þ þ 
14 MCC13 No P278S and S241P
both heterozygous
þ þ þ þ þ ?     
Abbreviations: MCC, Merkel cell carcinoma; MCV, Merkel cell polyoma virus; ND, not done; ?, data difficult to interpret.
1Exons 5–8 harbor 95% of the known p53 mutations (Vousden and Lu, 2002).
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The MCV-negative cell line MCC13 carried two different
mutations in exon 7 and exon 8 (Table 1). As we cannot
distinguish whether these two mutations affect the same or
different alleles, it is unknown whether all the p53 molecules
expressed in MCC13 are mutant or not. However, according
to the IARC (International Agency for Research on Cancer)
p53 mutation database, both loss-of-function and dominant-
negative effects on wild-type p53 have been described for the
P278S mutation in exon 8, suggesting that p53 is indeed
inactivated in this cell line (Petitjean et al., 2007). For the
p53 deletion mutant lacking amino acids 251–253, which
is present homo- or more likely hemizygously in the
MCV-positive line MS-1, functional data are not available.
Nevertheless, as several substitution mutants of the
deleted amino acids have been characterized as inactive,
this deletion mutant is likely to be inactivating (Petitjean
et al., 2007).
p53 expression and activity in MCC cell lines
Next we analyzed p53 mRNA and protein expression in nine
MCC cell lines using real-time PCR and immunoblot. In the
two p53 mutant cell lines (MCC13 and MS-1), the high mRNA
expression level correlated with high p53 protein expression
(Figure 1a). Accumulation of mutant p53 in tumor cells is a
well-known, although not yet fully understood, phenomenon
(Soussi, 2007). Among the seven p53 wild-type cell lines,
however, p53 protein expression levels were diverging and
did not correlate with mRNA expression. In two cell lines
(MCC26 and MKL-2), p53 protein was not detectable despite
p53 mRNA expression (Figure 1a), suggesting very strict
posttranscriptional repression of p53 expression. In the
remaining five p53 wild-type cell lines, p53 protein was
expressed at levels sufficient for detection by western blot.
To estimate the transcriptional activity of p53 in the different
MCC lines, we stably transduced the cells with a reporter gene
construct (pGreenFire) expressing green fluorescent protein
(GFP) under the control of a p53 response element. The
mean GFP expression was measured by flow cytometry and
normalized for the relative number of incorporated pGreen-
Fire copies as determined by real-time PCR. Surprisingly, the
normalized GFP expression from the pGreenFire construct did
not correlate with p53 expression (Figure 1a). As it has been
demonstrated that p53 reporter assays may sometimes yield
unspecific responses (Wischhusen et al., 2004), short hairpin
RNA (shRNA) knockdown of p53 was performed to determine
whether the observed GFP expression is p53 dependent. In the
two p53 mutant cell lines (MS-1 and MCC13), GFP reporter
expression was increased, and in MCC13, p21 was induced
upon p53 knockdown (Figure 1b), suggesting that predomi-
nantly an inhibitory activity of mutant p53 was eliminated
in these cells. In the two cell lines lacking detectable p53
expression (MCC26 and MKL-2), GFP expression remained
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Figure 1. p53 expression and transcriptional activity in Merkel cell carcinoma (MCC) cell lines. (a) Upper bar graph: real-time PCR analysis of p53 mRNA relative
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) depicted on a log scale. Immunoblot: p53 protein analysis. Lower bar graph: indicated MCC lines
(p53 mutant lines underlined) were stably transduced with a p53 reporter construct expressing green fluorescent protein (GFP; pGreenFire). Mean GFP
fluorescence was monitored by flow cytometry and normalized to the relative number of pGreenFire copies integrated into the cellular genome as determined by
real-time PCR. (b) The cells were infected with short hairpin RNA (shRNA) expression constructs containing either a scrambled (scr) or a sequence targeting p53.
Immunoblot: on day 4 after infection, total cell lysates were analyzed for the indicated proteins. Bar graph: mean GFP fluorescence of the scr control cells
minus that of p53 knockdown cells (p53-specific GFP expression). Mean values (±SD) derived from at least three independent experiments are shown (statistics:
one-sample t-test *Po0.05, **Po0.005, and ***Po0.0005). (c) Box-and-whiskers plot: p53-specific GFP expression of seven p53 wild-type MCC cell lines
compared with that of six p53 wild-type melanoma cell lines.
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almost unchanged on application of the p53 shRNA, implying
that in these cases GFP expression from the pGreenFire
construct is not driven by p53. In contrast, in the remaining
five p53 wild-type cell lines (UISO, WaGa, BroLi, MKL-1, and
PeTa), GFP expression was at least partially p53 dependent.
The p53-specific reporter gene activities in MCC lines, how-
ever, were low compared with the reporter gene activities
found in p53 wild-type melanoma cell lines (Figure 1c).
Nonetheless, p53 was observed to drive expression of its
target gene p21 in all five p53 wild-type MCC lines, as p53
knockdown led to decreased p21 levels (Figure 1b).
Obviously, however, p21 expression levels and p53 activity
are not sufficient to effectively restrict growth of these
proliferating tumor cells, evoking the question of what is
limiting p53 activity in MCC.
MCC-derived MCV TAs do not repress p53 activity when
overexpressed in cells with high endogenous p53 activity
Inhibition of p53 is a central feature of SV40 LT in transfor-
mation (Bargonetti et al., 1992; Jiang et al., 1993; Pipas and
Levine, 2001). Truncated MCV LTs expressed in MCC cells,
however, generally lack the C-terminal half of the protein
and thereby the potential p53-binding domain (Shuda et al.,
2008; Sastre-Garau et al., 2009). Nonetheless, the demon-
stration of p53 inhibiting activity for the N-terminus of SV40
LT (Quartin et al., 1994; Rushton et al., 1997) as well as for
SV40 sT (Gjoerup et al., 2000), and the recently published
observation of p53 mutations only in LT-negative MCCs (Sihto
et al., 2011), argue for a role of the MCV TAs in repression of
p53 in MCC.
To evaluate the capacity of the MCV TAs in inhibiting p53,
we utilized two p53 wild-type melanoma cell lines with high
p53-specific pGreenFire reporter gene activity (UACC-62 and
Mel-U) as a model system. Importantly, GFP expression in
these cells can almost completely be abrogated by p53
knockdown (data not shown). These cells were infected with
a lentiviral expression vector encoding MCV TALT279* (sT and
LT truncated at amino acid 279 resembling the stop codon
position of the MCC line WaGa). An SV40 TA (sT and LT)
expression construct encoding full-length SV40 LT was used
for control purposes. Expression of the different LT proteins
was confirmed by immunoblot (Figure 2a). The presence of
SV40 TA as well as of MCC-derived MCV TALT279* stimulated
cell cycle progression of the melanoma cell lines (data not
shown). In SV40 TA–transduced cells, increased S-phase entry
was accompanied by reduced p53 reporter gene activity, as
expected. However, on expression of MCV TALT279*, the p53
reporter gene activity was elevated in both cell lines
(Figure 2b). SV40 TA strongly increased p53 levels, as
previously reported (Rushton et al., 1997), whereas MCV
TALT279* elevated p53 expression only moderately (Figure 2a
and c). When p53 reporter gene activity is normalized to the
p53 protein levels, it becomes clear that SV40 TA strongly
suppresses p53 reporter gene activity, whereas MCC-derived
MCV TA does not (Figure 2d). A major regulator of p53
expression and activity is human double minute (HDM-2
(Harris and Levine, 2005). Therefore, we analyzed whether
ectopic TA expression would affect HDM-2 levels: HDM-2
was strongly increased upon SV40 TA but was unaffected by
MCV TALT279* expression (Figure 2a).
p53 transcriptional activity in MCC cells is not altered on
knockdown of MCV TAs
To confirm the lack of impact of MCV TAs on p53, we
analyzed p53 reporter gene activity following knockdown of
the MCV TAs in five MCV-positive MCC lines. On application
of an shRNA targeting LT and sT (Houben et al., 2010), p53
reporter gene activity remained unchanged in three cell lines
(WaGa, BroLi, and PeTa), whereas MKL-1 and MKL-2
displayed a small but statistically insignificant increase in
GFP expression (Figure 3). Expression of p53 and—more
importantly—expression of the p53 target genes p21,
HDM-2, and Bax, however, was not elevated upon TA
knockdown (Figure 3), suggesting that MCV sT and the
truncated MCV LT do not repress p53 function in any of the
five investigated cell lines. These findings together with the
inability of overexpressed MCV TALT279* to suppress p53
activity (Figure 2) and the observation of a p53 mutation in
the MCV-positive cell line MS-1 (Table 1) argue against an
inhibition of the p53 pathway in MCV-positive MCCs by the
MCV TAs.
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Figure 2. Overexpression of Merkel cell carcinoma (MCC)–derived Merkel
cell polyoma virus (MCV) T antigens (TAs) does not repress p53. The indicated
melanoma cell lines with high p53-specific green fluorescent protein (GFP)
reporter gene expression were infected with the indicated lentiviral vectors
containing simian virus 40 (SV40) or MCV TA gene, respectively. MCV
TALT279* codes for MCV small T antigen (sT) and for MCV large T antigen (LT)
truncated at amino acid 279, whereas SV40 TA contains wild-type sequences.
(a) Immunoblot with cell lysates harvested 4 days after infection. (b) Changes in
the mean GFP fluorescence measured on day 4. Mean values (±SD) from eight
independent experiments are given. (c) Immunoblot signals for p53 relative
to tubulin were quantified using the ImageJ software and data from five
independent experiments. Mean values (±SD) are given. (d) Changes in p53
reporter expression normalized to p53 expression derived as described in c.
*Po0.05, **Po0.005, and ***Po0.0005; one-sample t-test.
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p53 is activated by Nutlin-3a in 5 out of 7 p53 wild-type MCC
cell lines
Next we asked whether it is possible to reactivate p53 in MCC
cells. In this respect we tested two compounds. Cisplatin is a
DNA crosslinking antineoplastic agent frequently used for
treatment of metastasized MCC that may activate p53 via the
DNA damage response pathway (Tai et al., 2000; Pectasides
et al., 2006; Pabla et al., 2008). Nutlin-3a specifically inhibits
the E3 ubiquitin ligase HDM-2 (Secchiero et al., 2011) that is
expressed in all analyzed MCC cell lines with the exception of
MCC13 (Figure 1a). HDM-2 is the key player of several
negative autoregulatory loops of p53 that, in the absence of
p53-stabilizing signals, keep p53 levels low (Harris and
Levine, 2005). HDM-2 promotes proteasomal degradation of
the p53 protein through polyubiquitination of the C-terminus
(Kubbutat et al., 1997; Michael and Oren, 2003). Moreover,
HDM-2 binding can affect p53 through direct repression of its
transcriptional activity (Oliner et al., 1993).
The p53 mutant cell line MCC13 was not affected by
Nutlin3-a. In contrast, 5 out of 7 p53 wild-type cell lines
(UISO, WaGa, BroLi, MKL-1, and PeTa) responded to
Nutlin-3a treatment with increased GFP expression from the
p53 reporter (Figure 4a), induction of p53 expression, and
induction of at least two of the three p53 target proteins p21,
Bax, and HDM-2 (Figure 4b). This corresponded with induc-
tion of cell cycle arrest in the MCV-negative cell line UISO
and induction of apoptosis in the MCV-positive WaGa, BroLi,
MKL-1, and PeTa, as indicated by an increased sub-G1
population in cell cycle analysis after 40 hours of Nutlin-3a
treatment (Figure 4c, d and e). Induction of cell death by p53
reactivation distinguishes these MCC cell lines from many
other p53 wild-type cancer cell lines that, although frequently
responding with cell cycle arrest, are impaired in their
apoptotic response to Nutlin-3a (Tovar et al., 2006; Tseng
et al., 2010). The observed Nutlin-3a effects on MCC cells
were mediated by p53, as p53 knockdown reverted Nutlin-3a-
induced p53 reporter gene activity (data not shown) and
prevented cell cycle arrest or apoptosis (Figure 4f). Therefore,
repressed p53 activity due to HDM-2 activity might constitute
a major factor for growth and survival of these MCC cells.
Cisplatin did not provoke a clearcut p53 response.
Induction of p53 reporter gene activity was for most cell lines
much less pronounced compared with Nutlin-3a (Figure 4a),
there was no induction of the p53 target genes p21 and
HDM-2 (Figure 4b), and—although the sub-G1 fraction was
increased in all MCC cell lines (Figure 4e)—only in case of
BroLi the induction of cell death was p53 dependent
(Figure 4f). These results suggest that MCC cells have a general
defect in activation of wild-type p53 by the DNA damage
response pathway. This may be one of the reasons why this
tumor entity frequently progresses without p53 mutations
(Table 1 and see Van Gele et al., 2000; Lassacher et al.,
2008) and it may contribute to the limited long-term efficacy
of DNA-damaging agents and radiotherapy in advanced
MCC (Voog et al., 1999; Tai et al., 2000; Poulsen et al.,
2003, 2006; Becker, 2010).
Neither Cisplatin nor Nutlin-3a treatment led to detectable
p53 expression in MCC26 and MKL-2 cells (Figure 4b).
Therefore, the strict repression of p53 expression in these
two cell lines does not appear to be mediated by HDM-2. As
p53 mRNA is expressed in both cell lines (Figure 1a and
Table 1) either inhibition of p53 translation (e.g., by RNPC1;
Zhang et al., 2011) or HDM-2-independent degradation of
p53 are possible mechanisms for its repression. The latter may
play a role for MCC26 as incubation with the proteasome
inhibitor bortezomib provoked a weak p53 band in immu-
noblot analysis and a 3-fold increase in GFP expression from
the p53 reporter construct (data not shown).
Induction of p53 protein upon HDM-2 knockdown in four of five
Nutlin-3a-sensitive MCC cell lines
Although Nutlin-3a is regarded to be a highly selective
molecule targeting the HDM-2/p53 interaction (Patton et al.,
2006), inhibitor experiments always bear the risk to provoke
unspecific effects not related to the targeted protein. Therefore,
we aimed to complement the Nutlin-3a results by HDM-2
knockdown experiments. Application of an HDM-2 shRNA in
the five cell lines responding with p53 activation to Nutlin-3a
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Figure 3. Knockdown of Merkel cell polyoma virus (MCV) T antigens (TAs)
does not increase p53 activity in MCV-positive Merkel cell carcinoma (MCC)
cells. The indicated MCC cell lines stably transduced with a p53 reporter
construct (pGreenFire) were infected with a lentiviral short hairpin RNA
(shRNA) vector targeting both T antigens (Houben et al., 2010). On day 4 after
infection, green fluorescent protein (GFP) total cell lysates were analyzed by
immunoblot for the expression of the indicated proteins. Reporter gene
expression was measured by flow cytometry. Mean values (±SD), number of
independent experiments, and P-values of a one-sample t-test are annotated for
all cell lines examined. HDM-2, human double minute 2; LT, large T antigen;
scr, scrambled.
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let to induction of p53 and the p53 target p21 in WaGa, PeTa,
BroLi, and UISO (Figure 5), confirming that p53 in these cell
lines is controlled by HDM-2. Moreover, HDM-2 knockdown
like Nutlin-3a treatment provoked significant apoptosis in
WaGa, BroLi, and PeTa cells (Figure 5). In contrast, in
MKL-1 cells we could not induce any sign of p53 activation
with the HDM-2 shRNA. This, as well as the fact that in the
other cell lines induction of p53 expression is not as
pronounced as on Nutlin-3a treatment, is likely due to less
efficient and less synchronous repression of HDM-2 function
by the shRNA compared with Nutlin-3a.
Conclusion
In summary, we demonstrate that expression and activity of
p53—which is frequently wild type in MCC—is not repressed
by the MCV TAs but can be restored by HDM-2 antagonism.
This p53 reactivation induces cell cycle arrest or apoptosis in
the majority of MCC cell lines. Therefore, p53 reactivation by
inhibition of HDM-2 may be a possible future therapeutic
approach. Phase-I clinical trials using the Nutlin-3a-related
compound RG7112 for treatment of hematologic malignancies
(nCT00623870) and solid tumors (nCT00559533) are currently
ongoing (http://www.clinicaltrials.gov/). A clinically approved
HDM-2 inhibitor will hopefully become available in the future.
MATERIALS AND METHODS
Ethics statement
This study was conducted according to the Declaration of
Helsinki Principles and approved by the institutional review
board of Wu¨rzburg University Hospital (Ethikkommission der
Medizinischen Fakulta¨t der Universita¨t Wu¨rzburg; sequential study
number 124/05).
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Figure 4. Induction of p53-dependent apoptosis or cell cycle arrest by Nutlin-3a. The indicated cells stably transduced with a green fluorescent protein (GFP) p53
reporter construct were treated with 10mM Nutlin-3a or 10mg ml1 Cisplatin. After 24 hours, cells were analyzed by flow cytometry for GFP expression and cell
lysates were subjected to immunoblot analysis. Cell cycle analysis was performed after 40 hours of treatment. (a) Changes in GFP expression relative to
control cells are given (mean values (±SD) of at least five experiments). (b) Immunoblot analyzing of the indicated proteins. (c) Examples of histogram plots from
the cell cycle analysis. (d, e) Mean values (±SD) of at least five experiments for cells in S or sub-G1, respectively. (f) Results of the cell cycle analysis of
cells treated with Nutlin-3a or Cisplatin 4 days after infection with a lentiviral short hairpin RNA (shRNA) vector either targeting p53 or expressing a scrambled (scr)
control shRNA. *Po0.05, **Po0.005, and ***Po0.0005. (a) One-sample t-test. (d, e) Repeated measures analysis of variance (ANOVA).
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Cell culture
A series of cell lines from patients with histologically confirmed MCC
was established in our departments, including PeTa, AlDo, HeRo,
KaRi, and WoWe, as well as BroLi, WaGa, and LoKe. Procedures for
establishment of the three latter cell lines have been described
previously (Houben et al., 2010, 2012b). All cell lines mentioned
as well as MKL-1 (Shuda et al., 2008), MKL-2, and MS-1 (Houben
et al., 2010) harbor MCV DNA. In contrast, UISO (Ronan et al.,
1993), MCC13 (Leonard et al., 1995), and MCC 26 (Van Gele et al.,
2002) are MCV negative. MCC lines were grown in RPMI-1640
supplemented with 10% fetal calf serum, 100 U ml 1 penicillin, and
0.1 mg ml 1 streptomycin.
Sequence analysis of p53 exons 5–8
Genomic DNA was extracted from the different MCC cell lines and
subjected to seminested PCR using the primers previously reported
(Houben et al., 2011). The amplicons were sequenced by Sanger
sequencing.
Lentiviral p53 reporter gene assay and shRNA transfer
To establish cells with an integrated p53 reporter gene, the lentiviral
vector pGreenFire (System Biosciences, Mountain View, CA) was
used that codes for puromycin resistance and GFP under the control
of a p53-responsive element (4 50-CGACATGCCCGGGCATGT-30).
Knockdown of p53 or MCV TA expression was achieved by lentiviral
shRNA expression constructs described previously (Houben et al.,
2010, 2011). For overexpression of TAs in melanoma cell lines
carrying a GFP p53 reporter, a wild-type SV40 TA gene (Lin and
Simmons, 1991) or an MCV TA gene carrying a stop codon mutation
at codon 279 (Houben et al., 2012a) were cloned into the vector
pCDHred. This was done to allow identification of the infected cells
within a GFP-expressing population. pCDHred was derived from the
vector pCDH-CMV-MCS-EF1-copGFP (System Biosciences) by
replacing the copGFP sequence with a turboRFP. Infectious viruses
were raised by transfecting HEK293T cells and target cells were
infected as previously described (Houben et al., 2012a). Pure
populations carrying the pGreenFire reporter were selected by
culturing the cells in the presence of puromycin. GFP expression
from the reporter was analyzed by flow cytometry. The relative
presence of the reporter constructs in the genomic DNA of the
selected cells was analyzed by real-time PCR and calculated relative
to the highly repetitive DNA elements LINE1 using the DDCt method.
Immunoblot
Cells were lysed in RIPA buffer, protein concentration was deter-
mined and equal amounts of protein were resolved by SDS-PAGE.
Immunoblotting was performed as described previously (Houben
et al., 2012a). The following primary antibodies were applied: MCV
LT (CM2B4), p53 (D-01), p21 (C-19), HDM-2 (SMP14; all from Santa
Cruz Biotechnology, Santa Cruz, CA), Bax (2D2) (eBioscience,
San Diego, CA), SV40 LT (Abcam, Cambridge, MA), and tubulin
(Sigma-Aldrich, Taufkirchen, Germany).
Cell cycle analysis
DNA was stained with propidium iodide as described previously
(Houben et al., 2007). Analysis of the cellular DNA content was
performed on a FACSCanto flow cytometer (Becton Dickinson,
Heidelberg, Germany).
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